DoD FY2016 Autism Research Program Funding Opportunities

The FY16 Defense Appropriations Act provides $7.5 million (M) to the Department of Defense Autism Research Program (ARP) to support innovative, high-impact autism spectrum disorder research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, Research, Development, and Acquisition (DHA RDA) Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

The ARP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. FY16 ARP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in April 2016. Pre-application and application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the government.

 

http://cdmrp.army.mil/pubs/press/2016/16arppreann.shtml

 

Clinical Trial Award

Investigators at or above the level of Associate Professor (or equivalent)

  • Supports research with the potential to have a major impact on the treatment and/or management of autism spectrum disorder (ASD).
  • Preliminary data relevant to the proposed project are required.
  • Pre-application is required; application submission is by invitation only.
  • Behavioral, cognitive, and other non-pharmacological therapies
  • Pharmacological treatments in autism or well-defined subgroups of autism
  • Dissemination/Implementation of efficacious behavioral interventions (including measures of fidelity and outcomes)
  • Therapies to alleviate conditions co-occurring with ASD (e.g., sleep disturbances, gastrointestinal issues, aggression, depression, anxiety, attention deficit)
  • Maximum funding for the entire period of performance is $1,000,000 in direct costs (plus indirect costs)
  • Maximum period of performance is 4 years

Idea Development Award

Investigators at all academic levels (or equivalent)

  • Supports the development of innovative, high-impact ideas that advance the understanding of ASD and ultimately lead to improved outcomes.
  • Preliminary data are required.
  • Multiple Principal Investigator (PI) Option: Up to three investigators may collaborate on a single application, each of whom will be recognized as a PI and receive a separate award.
  • Pre-application is required; application submission is by invitation only.
  • Assessment of novel therapeutics using valid preclinical models
  • Environmental risk factors
  • Mechanisms of heterogeneous clinical expression of ASD
  • Mechanisms underlying conditions co-occurring with ASD (e.g., sleep disturbances, gastrointestinal issues, aggression, depression, anxiety, attention deficit)
  • Factors promoting success in key transitions to independence for individuals living with ASD
  • Maximum funding for the entire period of performance is $377,000 in direct costs (plus indirect costs)
  • For multiple PIs, the combined funding for all PIs for the entire period of performance may not exceed $377,000 in direct costs (plus indirect costs)
  • Maximum period of performance is 3 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

 

Applications must be submitted through the federal government’s single-entry portal, Grants.gov. Requests for email notification of the Program Announcements release may be sent to help@eBRAP.org. For more information about the OCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

 

Point of Contact:

CDMRP Public Affairs

301-619-9783

usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil